- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07297745
Estudio del Esterol Aldosterona-Híbrido para Guiar el Tratamiento Curable del Aldosteronismo Primario
Ensayo del Esteroides Híbrido de Aldosterona para Guiar el Tratamiento Curable del Hiperaldosteronismo Primario
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary Aldosteronism is a common but under-diagnosed condition, despite being a curable cause of secondary hypertension with significant long-term health consequences if left untreated. Once the diagnosis of primary aldosteronism is confirmed, subtype tests are required to demonstrate unilateral primary aldosteronism before curative surgery. Most patients need to undergo adrenal vein sampling, an invasive procedure performed under radiological guidance. However, this procedure is technically-challenging, with failure to cannulate both adrenal veins frequently leading to inconclusive results. Many patients worldwide may be offered surgery based on computed tomography imaging alone because of a lack of adrenal vein sampling expertise or a failed adrenal vein sampling result.
High hybrid hormones indicate a functional KCNJ5-mutant aldosterone-producing adenoma and, when coupled with computed tomography imaging, may provide a non-invasive alternative to adrenal vein sampling for identifying unilateral primary aldosteronism.
Ultimately, this trial aims to reduce the number of patients that will require an invasive adrenal vein sampling in future clinical diagnostics. This will improve access, and allow more patients to receive timely and curative treatment.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Troy H Puar, FRCP, PhD
- Número de teléfono: 67888833
- Correo electrónico: troy_puar@cgh.com.sg
Ubicaciones de estudio
-
-
-
Singapore, Singapur
- Reclutamiento
- National University Hospital
-
Contacto:
- Ada Teo
- Número de teléfono: +65 6908 2222
- Correo electrónico: ada_ed_teo@nuhs.edu.sg
-
Investigador principal:
- Ada Teo
-
Singapore, Singapur
- Reclutamiento
- Singapore General Hospital
-
Contacto:
- Swee Du Soon
- Número de teléfono: +65 6222 3322
- Correo electrónico: swee.du.soon@singhealth.com.sg
-
Investigador principal:
- Swee Du Soon
-
Singapore, Singapur
- Aún no reclutando
- Khoo Teck Puat Hospital
-
Contacto:
- Niyati Jauhar
- Número de teléfono: +65 6555 8000
- Correo electrónico: jauhar.niyati@nhghealth.com.sg
-
Investigador principal:
- Niyati Jauhar
-
Singapore, Singapur
- Aún no reclutando
- Tan Tock Seng Hospital
-
Contacto:
- Lai Tian Rui Ray
- Número de teléfono: +65 6357 3078
- Correo electrónico: ray.tr.lai@nhghealth.com.sg
-
Investigador principal:
- Lai Tian Rui Ray
-
Singapore, Singapur
- Reclutamiento
- Sengkang General Hospital
-
Contacto:
- Matthew Chuah
- Número de teléfono: +65 6930 5000
- Correo electrónico: matthew.chuah@singhealth.com.sg
-
Investigador principal:
- Matthew Chuah Bingfeng
-
-
Singapore
-
Singapore, Singapore, Singapur, 529889
- Reclutamiento
- Changi General Hospital
-
Contacto:
- Troy H Puar, FRCP, PhD
- Número de teléfono: +65 68503967
- Correo electrónico: troy_puar@cgh.com.sg
-
Investigador principal:
- Troy H Puar, FRCP, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.
- Willing to undergo subtype testing with adrenal vein sampling and/or molecular imaging (Positron Emission Tomography/Computed Tomography, PET/CT).
- Keen for surgical treatment if shown to have unilateral primary aldosteronism.
Exclusion Criteria:
- Inability to provide written informed consent.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Hybrid hormones
Previous studies have shown that hybrid hormones are elevated in patients with unilateral primary aldosteronism who have large, visible adenomas in their adrenal glands. These tumors harbour a somatic KCNJ5 mutation and are also most likely to be cured of hypertension after surgery. Hence, the investigators hypothesize that high hybrid hormones levels, in the presence of an adenoma on a computed tomography imaging would identify study participants who can proceed to surgery. |
Participants will have a baseline blood sample taken so the investigators can measure the adrenal steroid biomarkers 18-oxocortisol, 18-hydroxylcortisol and other steroids. The collected plasma or serum will then be analyzed in the laboratory using validated methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to determine the levels of these biomarkers. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants with complete biochemical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Periodo de tiempo: 6 months
|
Proportion of participants with correction of hypokalaemia and normalisation of aldosterone-renin-ratio following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Proportion of participants with KCNJ5-mutant aldosterone producing adenoma/nodule
Periodo de tiempo: 6 months
|
Proportion of participants with histopathology and genetic confirmation of KCNJ5-mutant aldosterone producing adenoma/nodule in resected adrenals. |
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of participants with complete clinical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Periodo de tiempo: 6 months
|
Proportion of participants with reduction in blood pressure and reduction anti-hypertensive medication following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Cost-effectiveness of using hybrid hormones coupled with computed tomography imaging versus other subtyping tests including adrenal vein sampling and/or molecular imaging in diagnosing participants with unilateral primary aldosteronism
Periodo de tiempo: 6 months
|
Cost-effectiveness of the diagnostic course will be calculated by using calculated costs per quality-adjusted life years (QALYs) |
6 months
|
|
Diagnostic criteria using hybrid hormones/ steroid profiling coupled with computed tomography imaging
Periodo de tiempo: 6 months
|
The criteria of hybrid hormones/ steroid profiling coupled with computed tomography imaging which offer the best sensitivity and specificity for lateralization of aldosterone-producing adenoma. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Troy Puar, FRCP, PhD, Changi General Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TARGET-PA
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .